CliffBio
biologic

Lunsumio Velo

mosunetuzumab-axgb

Loss of exclusivityDecember 2037projected — 12-year biologic exclusivity estimate
CompanyGenentech →View the full company profile on CliffBio

Drug detail

Brand nameLunsumio Velo
Active ingredientmosunetuzumab-axgb
Strength5MG/0.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalDecember 2025
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Lunsumio Velo patent cliff — loss of exclusivity December 2037 | CliffBio